Just days after Eli Lilly announced plans to cut the price of its insulin products in the US, Novo Nordisk has followed suit with reductions of up to 75% from the start of next year. The discount ...
Investing.com -- Bernstein analysts told investors in a note Tuesday that Eli Lilly (NYSE:LLY) is gaining ground in the GLP-1 market, edging closer to market share parity with Novo Nordisk (NYSE ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback